The leading business intelligence supplier, has discharged its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, that provides in-depth analysis of 4 key therapeutic indications inside the Asia-Pacific (APAC) solid tumors market – bladder cancer, gonad cancer, carcinoma and adenocarcinoma – covering the four countries of Australia, China, Republic of India and Japan. The report provides associate estimation of market size for 2012, beside market forecast till 2019. It additionally covers sickness medicine, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid growth sorts.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/solid-tumors-market-in-asia-pacific-to-2019-new-drug-approvals-and-anticipated-product-launches-to-trigger-a-shift-in-treatment-paradigm-to-targeted-therapies
The value of the solid tumors market within the APAC region amounted to associate calculable $1 billion in 2012 and is predicted to register a modest Compound Annual rate of growth (CAGR) of twelve.3% to succeed in $2.3 billion in 2019. The key drivers for growth during this market include: new product approvals in gonad, exocrine gland and adenocarcinomas; expected launches from the promising gonad and prostate cancer pipelines; and magnified penetration thanks to the anticipated implementation of welfare in China. Conversely, the expansion of the market during this region may face some proscribing influences, including: the recent implementation of a worth ceiling on essential medication in India; anticipated valuation restrictions in China; low access and penetration; and worth erosion thanks to generic competition.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals within the bladder cancer, gonad cancer, carcinoma and adenocarcinoma within the four APAC markets of Australia, China, Republic of India and Japan.
The report includes:
Reasons to shop for
Table of Content
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Solid Tumors Market in Asia Pacific to a pair of019 - Introduction
2.1 Introduction
3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 identification
3.1.5 Classification
3.1.6 medicine
3.1.7 Prognosis and sickness Staging
3.1.8 Treatment choices
3.2 gonad Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 identification
3.2.5 Classification
3.2.6 medicine
3.2.7 Prognosis and sickness Staging
3.2.8 Treatment choices
3.3 carcinoma
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 identification
3.3.5 Classification
3.3.6 medicine
3.3.7 Prognosis and sickness Staging
3.3.8 Treatment algorithmic rule
3.4 adenocarcinoma
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 identification
3.4.6 Classification
3.4.7 medicine
3.4.8 Prognosis and sickness Staging
3.4.9 Treatment choices
4 Solid Tumors Market in Asia Pacific to 2019 - Marketed merchandise
4.1 Bladder Cancer
4.2 gonad Cancer
4.3 carcinoma
4.4 adenocarcinoma
4.5 Key Marketed merchandise
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 antibiotic
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Sales : sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.com/
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/solid-tumors-market-in-asia-pacific-to-2019-new-drug-approvals-and-anticipated-product-launches-to-trigger-a-shift-in-treatment-paradigm-to-targeted-therapies
The value of the solid tumors market within the APAC region amounted to associate calculable $1 billion in 2012 and is predicted to register a modest Compound Annual rate of growth (CAGR) of twelve.3% to succeed in $2.3 billion in 2019. The key drivers for growth during this market include: new product approvals in gonad, exocrine gland and adenocarcinomas; expected launches from the promising gonad and prostate cancer pipelines; and magnified penetration thanks to the anticipated implementation of welfare in China. Conversely, the expansion of the market during this region may face some proscribing influences, including: the recent implementation of a worth ceiling on essential medication in India; anticipated valuation restrictions in China; low access and penetration; and worth erosion thanks to generic competition.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals within the bladder cancer, gonad cancer, carcinoma and adenocarcinoma within the four APAC markets of Australia, China, Republic of India and Japan.
The report includes:
- Disease summary, yet as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC solid tumors market from 2012 to 2019
- Major marketed merchandise within the APAC region for all four solid growth sorts coated
- In-depth pipeline analysis for all four solid growth sorts
- Key drivers and restraints that have had and area unit expected to own a major impact upon the market
- Key licensing and co-development agreements within the solid tumors market
Reasons to shop for
- The report can enhance your decision-making capability by permitting you to:
- Align your product portfolio to the markets with high growth potential
- Develop market entry and growth methods by distinctive the potential regions and therapeutic segments poised for robust growth
- Devise a additional effectively tailored country strategy through the understanding of key drivers and barriers within the solid tumors market
- Develop key strategic initiatives primarily based upon associate understanding of key focus areas and leading firms
- Accelerate and strengthen your market position by distinctive key firms for mergers, acquisitions and strategic partnerships
To check out the complete table of contents, visit: http://www.marketresearchreports.biz/sample/sample/175327
Table of Content
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Solid Tumors Market in Asia Pacific to a pair of019 - Introduction
2.1 Introduction
3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 identification
3.1.5 Classification
3.1.6 medicine
3.1.7 Prognosis and sickness Staging
3.1.8 Treatment choices
3.2 gonad Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 identification
3.2.5 Classification
3.2.6 medicine
3.2.7 Prognosis and sickness Staging
3.2.8 Treatment choices
3.3 carcinoma
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 identification
3.3.5 Classification
3.3.6 medicine
3.3.7 Prognosis and sickness Staging
3.3.8 Treatment algorithmic rule
3.4 adenocarcinoma
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 identification
3.4.6 Classification
3.4.7 medicine
3.4.8 Prognosis and sickness Staging
3.4.9 Treatment choices
4 Solid Tumors Market in Asia Pacific to 2019 - Marketed merchandise
4.1 Bladder Cancer
4.2 gonad Cancer
4.3 carcinoma
4.4 adenocarcinoma
4.5 Key Marketed merchandise
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 antibiotic
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Sales : sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.com/
0 comments:
Post a Comment